1. |
Vingolo EM, Steindl K, Forte R, et al. Autosomal dominant simple microphthalmos[J]. J Med Genet, 1994, 31(9): 721-725. DOI: 10.1136/jmg.31.9.721.
|
2. |
Jung KI, Yang JW, Lee YC, et al. Cataract surgery in eyes with nanophthalmos and relative anterior microphthalmos[J]. Am J Ophthalmol, 2012, 153(6): 1161-1168. DOI: 10.1016/j.ajo.2011.12.006.
|
3. |
Relhan N, Jalali S, Pehre N, et al. High-hyperopia database, part Ⅰ: clinical characterisation including morphometric (biometric) differentiation of posterior microphthalmos from nanophthalmos[J]. Eye (Lond), 2016, 30(1): 120-126. DOI: 10.1038/eye.2015.206.
|
4. |
Carricondo PC, Andrade T, Prasov L, et al. Nanophthalmos: a review of the clinical spectrum and genetics[J/OL]. J Ophthalmol, 2018, 2018: 2735465[2018-05-09]. http://europepmc.org/article/MED/29862063. DOI: 10.1155/2018/2735465..
|
5. |
Siggs OM, Awadalla MS, Souzeau E. The genetic and clinical landscape of nanophthalmos and posterior microphthalmos in an Australian cohort[J]. Clin Genet, 2020, 97(5): 764-769. DOI: 10.1111/cge.13722.
|
6. |
Sundin OH, Leppert GS, Silva ED, et al. Extreme hyperopia is the result of null mutations in MFRP, which encodes a frizzled-related protein[J]. Proc Natl Acad Sci USA, 2005, 102(27): 9553-9558. DOI: 10.1073/pnas.0501451102.
|
7. |
Gal A, Rau I, El Matri L, et al. Autosomal-recessive posterior microphthalmos is caused by mutations in PRSS56, a gene encoding a trypsin-like serine protease[J]. Am J Hum Genet, 2011, 88(3): 382-390. DOI: 10.1016/j.ajhg.2011.02.006.
|
8. |
Orr A, Dube MP, Zenteno JC, et al. Mutations in a novel serine protease PRSS56 in families with nanophthalmos[J]. Mol Vis, 2011, 17: 1850-1861.
|
9. |
Sundin OH, Dharmaraj S, Bhutto IA, et al. Developmental basis of nanophthalmos: MFRP is required for both prenatal ocular growth and postnatal emmetropization[J]. Ophthalmic Genet, 2008, 29(1): 1-9. DOI: 10.1080/13816810701651241.
|
10. |
Nair KS, Hmani-Aifa M, Ali Z, et al. Alteration of the serine protease PRSS56 causes angle-closure glaucoma in mice and posterior microphthalmia in humans and mice[J]. Nat Genet, 2011, 43(6): 579-584. DOI: 10.1038/ng.813.
|
11. |
Awadalla MS, Burdon KP, Souzeau E, et al. Mutation in TMEM98 in a large white kindred with autosomal dominant nanophthalmos linked to 17p12-q12[J]. JAMA Ophthalmol, 2014, 132(8): 970-977. DOI: 10.1001/jamaophthalmol.2014.946.
|
12. |
Khorram D, Choi M, Roos BR, et al. Novel TMEM98 mutations in pedigrees with autosomal dominant nanophthalmos[J]. Mol Vis, 2015, 21: 1017-1023.
|
13. |
Cross SH, McKie L, Keighren M, et al. Missense mutations in the human nanophthalmos gene TMEM98 cause retinal defects in the mouse[J]. Invest Ophthalmol Vis Sci, 2019, 60(8): 2875-2887. DOI: 10.1167/iovs.18-25954.
|
14. |
Othman MI, Sullivan SA, Skuta GL, et al. Autosomal dominant nanophthalmos (NNO1) with high hyperopia and angle-closure glaucoma maps to chromosome 11[J]. Am J Hum Genet, 1998, 63(5): 1411-1418. DOI: 10.1086/302113.
|
15. |
Garnai SJ, Brinkmeier ML, Emery B, et al. Variants in myelin regulatory factor (MYRF) cause autosomal dominant and syndromic nanophthalmos in humans and retinal degeneration in mice[J/OL]. PLoS Genet, 2019, 15(5): 1008130[2019-05-02]. http://europepmc.org/article/MED/31048900. DOI: 10.1371/journal.pgen.1008130.
|
16. |
Guo C, Zhao Z, Chen D, et al. Detection of clinically relevant genetic variants in Chinese patients with nanophthalmos by trio-based whole-genome sequencing study[J]. Invest Ophthalmol Vis Sci, 2019, 60(8): 2904-2913. DOI: 10.1167/iovs.18-26275.
|
17. |
Pinz H, Pyle LC, Li D, et al. De novo variants in myelin regulatory factor (MYRF) as candidates of a new syndrome of cardiac and urogenital anomalies[J]. Am J Med Genet A, 2018, 176(4): 969-972. DOI: 10.1002/ajmg.a.38620.
|
18. |
Rossetti LZ, Glinton K, Yuan B, et al. Review of the phenotypic spectrum associated with haploinsufficiency of MYRF[J]. Am J Med Genet A, 2019, 179(7): 1376-1382. DOI: 10.1002/ajmg.a.61182.
|
19. |
Huang H, Teng P, Du J, et al. Interactive repression of MYRF self-cleavage and activity in oligodendrocyte differentiation by TMEM98 protein[J]. J Neurosci, 2018, 38(46): 9829-9839. DOI: 10.1523/jneurosci.0154-18.2018.
|
20. |
Yardley J, Leroy BP, Hart-Holden N, et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC)[J]. Invest Ophthalmol Vis Sci, 2004, 45(10): 3683-3689. DOI: 10.1167/iovs.04-0550.
|
21. |
Zenteno JC, Buentello-Volante B, Ayala-Ramirez R, et al. Homozygosity mapping identifies the crumbs homologue 1(Crb1) gene as responsible for a recessive syndrome of retinitis pigmentosa and nanophthalmos[J]. Am J Med Genet A, 2011, 155A(5): 1001-1006. DOI: 10.1002/ajmg.a.33862.
|
22. |
Li H, Wang JX, Wang CY, et al. Localization of a novel gene for congenital nonsyndromic simple microphthalmia to chromosome 2q11-14[J]. Human Genetics, 2008, 122(6): 589-593. DOI: 10.1007/s00439-007-0435-y.
|
23. |
Duke-Elder S. Normal and abnormal development[M]//Duke-Elder S. System of ophthalmology. St Louis: Mosby, 1964: 488-495.
|
24. |
Weiss AH, Kousseff BG, Ross EA, et al. Simple microphthalmos[J]. Arch Ophthalmol, 1989, 107(11): 1625-1630. DOI: 10.1001/archopht.1989.01070020697031.
|
25. |
Zheng T, Chen Z, Xu J, et al. Outcomes and prognostic factors of cataract surgery in adult extreme microphthalmos with axial length<18 mm or corneal diameter<8 mm[J]. Am J Ophthalmol, 2017, 184: 84-96. DOI: 10.1016/j.ajo.2017.09.028.
|
26. |
Spitznas M, Gerke E, Bateman JB. Hereditary posterior microphthalmos with papillomacular fold and high hyperopia[J]. Arch Ophthalmol, 1983, 101(3): 413-417. DOI: 10.1001/archopht.1983.01040010413014.
|
27. |
Brockhurst RJ. Nanophthalmos with uveal effusion: a new clinical entity[J]. Arch Ophthalmol, 1975, 93(12): 1989-1999. DOI: 10.1001/archopht.1975.01010020923001.
|
28. |
Uyama M, Takahashi K, Kozaki J, et al. Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology[J]. Ophthalmology, 2000, 107(3): 441-449. DOI: 10.1016/s0161-6420(99)00141-4.
|
29. |
Forrester JV, Lee WR, Kerr PR, et al. The uveal effusion syndrome and trans-scleral flow[J]. Eye (Lond), 1990, 4(t2): 354-365. DOI: 10.1038/eye.1990.48.
|
30. |
Demircan A, Yesilkaya C, Altan C, et al. Foveal avascular zone area measurements with optical coherence tomography angiography in patients with nanophthalmos[J]. Eye (Lond), 2019, 33(3): 445-450. DOI: 10.1038/s41433-018-0236-7.
|
31. |
Yalvac IS, Satana B, Ozkan G, et al. Management of glaucoma in patients with nanophthalmos[J]. Eye (Lond), 2008, 22(6): 838-843. DOI: 10.1038/sj.eye.6702742.
|
32. |
Altintas AK, Acar MA, Yalvac IS, et al. Autosomal recessive nanophthalmos[J]. Acta Ophthalmol Scand, 1997, 75(3): 325-328. DOI: 10.1111/j.1600-0420.1997.tb00788.x.
|
33. |
王华, 唐炘, 王涛. 拉坦前列素滴眼液治疗真性小眼球继发闭角型青光眼的疗效观察[J]. 中国实用眼科杂志, 2011, 29(8): 772-774. DOI: 10.3760/cma.j.issn.1006-4443.2011.08.007.Wang H, Tang X, Wang T. The effect of latanoproston the treatment of nanophthalmos combined with angle closure glaucoma[J]. Chin J Pract Ophthalmol, 2011, 29(8): 772-774. DOI: 10.3760/cma.j.issn.1006-4443.2011.08.007.
|
34. |
余敏斌, 黄圣松, 叶天才. 真性小眼球继发青光眼的治疗[J]. 中国实用眼科杂志, 2002, 20(9): 677-679. DOI: 10.3760/cma.j.issn.1006-4443.2002.09.012.Yu MB, Huang SS, Ye TC. The management of glaucoma in nanophthalmic patients[J]. Chin J Pract Ophthalmol, 2002, 20(9): 677-679. DOI: 10.3760/cma.j.issn.1006-4443.2002.09.012.
|
35. |
Burgoyne C, Tello C, Katz LJ. Nanophthalmia and chronic angle-closure glaucoma[J]. J Glaucoma, 2002, 11(6): 525-528. DOI: 10.1097/00061198-200212000-00013.
|
36. |
Elagouz M, Stanescu-Segall D, Jackson TL. Uveal effusion syndrome[J]. Surv Ophthalmol, 2010, 55(2): 134-145. DOI: 10.1016/j.survophthal.2009.05.003.
|
37. |
黎铧, 李娟娟, 王萍, 等. 脉络膜渗漏综合征多种眼底影像特征对比观察[J]. 中华眼底病杂志, 2016, 32(6): 639-641. DOI: 10.3760/cma.j.issn.1005-1015.2016.06.018.Li Y, Li JJ, Wang P, et al. Contrastive observation of fundus image characteristics of choroidal leakage syndrome[J]. Chin J Ocul Fundus Dis, 2016, 32(6): 639-641. DOI: 10.3760/cma.j.issn.1005-1015.2016.06.018.
|
38. |
Gass JD. Uveal effusion syndrome: a new hypothesis concerning pathogenesis and technique of surgical treatment[J]. Retina, 1983, 3(3): 159-163. DOI: 10.1097/00006982-198300330-00003.
|
39. |
Besirli CG, Johnson MW. Uveal effusion syndrome and hypotony maculopathy[M]//Stephen JR. Retina. 5th ed. Philadelphia: Saunders, 2013: 1306-1317.
|
40. |
Mansour A, Stewart MW, Shields CL. Extensive circumferential partial-thickness sclerectomy in eyes with extreme nanophthalmos and spontaneous uveal effusion[J]. Br J Ophthalmol, 2019, 103(12): 1862-1867. DOI: 10.1136/bjophthalmol-2018-313702.
|
41. |
Khatri A, Singh S, Joshi K, et al. Quadrantic vortex vein decompression with subretinal fluid drainage for manangement of Nanophthalmic choroidal effusions: a review of literature and case series[J]. BMC Ophthalmol, 2019, 19(1): 210. DOI: 10.1186/s12886-019-1213-z.
|